Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Geron Corp

GERN ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$1.47

▼ -4.23%

Market Cap $944.44M · Vol 1.88M

Key Metrics

P/E Ratio

N/A

FWD: 46.61

Market Cap

$944.44M

Small Cap

Div Yield

N/A

EPS Growth

+75.38%

YoY

RSI (14)

49.50

Momentum

Beta

0.62

vs Market

52W High

$2.00

26.50% below

52W Low

$1.04

41.35% above

Volume

1.88M

Avg 2.33M

P/B

3.74

Price-to-book

ROE

N/A

Return on equity

Free Float

99.09%

Public shares

Shariah Compliance8 STANDARDS

✗ Geron Corp (GERN) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GERN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.68%

+6.52%

+5.00%

-10.91%

YTD

+11.36%

+1.38%

-50.67%

+20.49%

Financials & Valuation

TTM · Annual

Total Revenue	$183.88M
Net Income	$-83,500,000.00
Revenue Growth (YoY)	+17.22%
Gross Margin	97.42%
Operating Margin	-28.04%
Net Profit Margin	-45.41%
ROE	N/A
ROA · ROIC	-14.34% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	46.61
PEG Ratio	N/A
P/S	4.79
P/B	3.74
P/FCF	N/A
EPS Growth	+75.38%
Outstanding Shares	642.47M

Technical Indicators

50-Day SMA	$1.37
200-Day SMA	$1.41
RSI (14)	49.50
Beta	0.62
52-Week High	$2.00
52-Week Low	$1.04

Volume Today	1.88M
Avg Daily Volume (30D)	2.33M
Relative Volume	0.80x
Volatility (10D)	119.20
Volatility (30D)	81.46
Free Float	99.09%

Analyst Consensus

BUY

Current Price $1.47

Mean Target $4.25

52W Low$1.04 52W High$2.00

Current

Target

$1.04 $2.00

Current Analyst target

+189.12% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S6TSX4

ISINUS3741631036

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.